These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
643 related articles for article (PubMed ID: 28446239)
1. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells. Thibault B; Jean-Claude B J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239 [TBL] [Abstract][Full Text] [Related]
2. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer. Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749 [TBL] [Abstract][Full Text] [Related]
3. Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs. Puvanenthiran S; Essapen S; Seddon AM; Modjtahedi H Int J Oncol; 2016 Nov; 49(5):1825-1838. PubMed ID: 27599579 [TBL] [Abstract][Full Text] [Related]
4. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342 [TBL] [Abstract][Full Text] [Related]
5. Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways. Lai YH; Chen MH; Lin SY; Lin SY; Wong YH; Yu SL; Chen HW; Yang CH; Chang GC; Chen JJ Oncotarget; 2015 Sep; 6(28):26252-65. PubMed ID: 26312766 [TBL] [Abstract][Full Text] [Related]
6. Activity of the multikinase inhibitor dasatinib against ovarian cancer cells. Konecny GE; Glas R; Dering J; Manivong K; Qi J; Finn RS; Yang GR; Hong KL; Ginther C; Winterhoff B; Gao G; Brugge J; Slamon DJ Br J Cancer; 2009 Nov; 101(10):1699-708. PubMed ID: 19861960 [TBL] [Abstract][Full Text] [Related]
7. Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status. Formisano L; D'Amato V; Servetto A; Brillante S; Raimondo L; Di Mauro C; Marciano R; Orsini RC; Cosconati S; Randazzo A; Parsons SJ; Montuori N; Veneziani BM; De Placido S; Rosa R; Bianco R Oncotarget; 2015 Sep; 6(28):26090-103. PubMed ID: 26325669 [TBL] [Abstract][Full Text] [Related]
8. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells. Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343 [TBL] [Abstract][Full Text] [Related]
9. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer. Wen W; Wu J; Liu L; Tian Y; Buettner R; Hsieh MY; Horne D; Dellinger TH; Han ES; Jove R; Yim JH Mol Cancer; 2015 May; 14():100. PubMed ID: 25928246 [TBL] [Abstract][Full Text] [Related]
10. Target modulation by a kinase inhibitor engineered to induce a tandem blockade of the epidermal growth factor receptor (EGFR) and c-Src: the concept of type III combi-targeting. Rao S; Larroque-Lombard AL; Peyrard L; Thauvin C; Rachid Z; Williams C; Jean-Claude BJ PLoS One; 2015; 10(2):e0117215. PubMed ID: 25658745 [TBL] [Abstract][Full Text] [Related]
11. Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines. Stanley A; Ashrafi GH; Seddon AM; Modjtahedi H Sci Rep; 2017 Jun; 7(1):3964. PubMed ID: 28638122 [TBL] [Abstract][Full Text] [Related]
12. The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling. Booth L; Roberts JL; Tavallai M; Webb T; Leon D; Chen J; McGuire WP; Poklepovic A; Dent P Oncotarget; 2016 Apr; 7(15):19620-30. PubMed ID: 26934000 [TBL] [Abstract][Full Text] [Related]
13. SRC promotes survival and invasion of lung cancers with epidermal growth factor receptor abnormalities and is a potential candidate for molecular-targeted therapy. Leung EL; Tam IY; Tin VP; Chua DT; Sihoe AD; Cheng LC; Ho JC; Chung LP; Wong MP Mol Cancer Res; 2009 Jun; 7(6):923-32. PubMed ID: 19491201 [TBL] [Abstract][Full Text] [Related]
14. A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149). Hirte H; Oza A; Swenerton K; Ellard SL; Grimshaw R; Fisher B; Tsao M; Seymour L Gynecol Oncol; 2010 Sep; 118(3):308-12. PubMed ID: 20646751 [TBL] [Abstract][Full Text] [Related]
15. Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2. Chang CM; Chang PY; Tu MG; Lu CC; Kuo SC; Amagaya S; Lee CY; Jao HY; Chen MY; Yang JS Oncol Rep; 2012 Nov; 28(5):1799-807. PubMed ID: 22923287 [TBL] [Abstract][Full Text] [Related]
16. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells. Kim EM; Mueller K; Gartner E; Boerner J J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511 [TBL] [Abstract][Full Text] [Related]
17. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436 [TBL] [Abstract][Full Text] [Related]
18. [The combination of dasatinib and gefitinib enhances the killing effect of gefitinib on HCC827 lung cancer cells]. Wang Z; Li L; Shao Z; Xie H; Yang F; Zhou N Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 May; 32(5):595-9. PubMed ID: 27126935 [TBL] [Abstract][Full Text] [Related]
19. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Hiscox S; Morgan L; Green TP; Barrow D; Gee J; Nicholson RI Breast Cancer Res Treat; 2006 Jun; 97(3):263-74. PubMed ID: 16333527 [TBL] [Abstract][Full Text] [Related]
20. The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer. Gui T; Shen K Cancer Epidemiol; 2012 Oct; 36(5):490-6. PubMed ID: 22818908 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]